ICML 2023 | CC-99282 ± rituximab for R/R NHL: Phase I/II trial interim analysis
Jean-Marie Michot, MD, Gustave Roussy Institute, Villejuif, France, discusses the results from an interim analysis of a Phase I/II trial investigating CC-99282 as a monotherapy or in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL; NCT03930953). This trial enrolled patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who had failed two prior lines of therapy, or patients with DLBCL who had failed a single line of therapy and were ineligible for stem cell transplantation (SCT). Dr Michot discusses the tolerability profile of the treatment, and shares early data regarding the efficacy of CC-99282. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
